inotuzumab ozogamicin (besponsa) Report issue

Biologics mAb ADC Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: ozogamicin
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$738.6860 - $949.4840

Australia

$10163.5938
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

besponsa | cmc544 | cmc 544 | cmc-544 | inotuzumab ozogamicin | inotuzumab ozogamycin | pf-05208773 | way-207294 | way-207294 cmc-544

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue